Raytoei shared a bullish thesis on Constellation Brands, Inc. on Valueinvesting subreddit. STZ’s share was trading at $175.83 on July 29th, with trailing and forward P/E of 18.50 and 13.76. Jim Cramer called them the benchmark of a bad alcohol business. STZ appears undervalued with $10 billion in revenue, 2.49% dividend yield, and strong returns.

Despite STZ’s strong fundamentals and growth potential, the market prices in only 1.09% perpetual growth, well below management guidance and analyst projections. Overhangs like obesity drugs, Gen Z preferences, and tariff concerns may be causing pessimism. However, STZ’s outlook suggests mid- to high-single-digit growth in the future, providing a contrarian opportunity for investors.

The current valuation of Constellation Brands, Inc. reflects an overly cautious stance, offering a contrarian opportunity for long-term investors who believe in normalization and reacceleration of growth. Analysts project ~7% growth, aligning more with historical performance than market-implied pessimism. Management anticipates mid- to high-single-digit growth in the future, providing potential upside for investors.

Read more at Yahoo Finance: Constellation Brands, Inc. (STZ): A Bull Case Theory